- Home
- KURA vs UVE Comparison
KURA vs UVE Comparison
Compare KURA & UVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KURA
- UVE
- Stock Information
- Founded
- KURA 2014
- UVE 1990
- Country
- KURA United States
- UVE United States
- Employees
- KURA N/A
- UVE N/A
- Industry
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- UVE Property-Casualty Insurers
- Sector
- KURA Health Care
- UVE Finance
- Exchange
- KURA Nasdaq
- UVE Nasdaq
- Market Cap
- KURA 713.5M
- UVE 666.1M
- IPO Year
- KURA N/A
- UVE 1992
- Fundamental
- Price
- KURA $10.26
- UVE $31.44
- Analyst Decision
- KURA Strong Buy
- UVE
- Analyst Count
- KURA 13
- UVE 0
- Target Price
- KURA $25.00
- UVE N/A
- AVG Volume (30 Days)
- KURA 2.0M
- UVE 219.9K
- Earning Date
- KURA 11-04-2025
- UVE 10-23-2025
- Dividend Yield
- KURA N/A
- UVE 2.45%
- EPS Growth
- KURA N/A
- UVE 68.88
- EPS
- KURA N/A
- UVE 4.23
- Revenue
- KURA $83,279,000.00
- UVE $1,580,798,000.00
- Revenue This Year
- KURA $68.63
- UVE $1.87
- Revenue Next Year
- KURA $141.59
- UVE N/A
- P/E Ratio
- KURA N/A
- UVE $7.43
- Revenue Growth
- KURA N/A
- UVE 4.61
- 52 Week Low
- KURA $5.41
- UVE $18.72
- 52 Week High
- KURA $19.73
- UVE $33.00
- Technical
- Relative Strength Index (RSI)
- KURA 57.62
- UVE 66.70
- Support Level
- KURA $9.08
- UVE $30.57
- Resistance Level
- KURA $11.06
- UVE $33.00
- Average True Range (ATR)
- KURA 0.61
- UVE 1.01
- MACD
- KURA -0.01
- UVE 0.17
- Stochastic Oscillator
- KURA 59.85
- UVE 69.50
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
About UVE UNIVERSAL INSURANCE HOLDINGS INC
Universal Insurance Holdings Inc is a private personal residential homeowner insurance company. The company develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners' lines of business and performs substantially all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The company generates revenue from the collection of premiums, earned net interest and dividend income from the investment portfolio, the collection of reinsurance recoverable and financing fees. The company's primary insurance subsidiaries, (UPCIC) and (APPCIC) provide insurance for personal residential: homeowners, renters/tenants, condo unit owners, and other related coverages.